Phaseline

Targets › P2Y12

P2Y12: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology.

Open in Phaseline: the race on P2Y12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tianjin Institute of Pharmaceutical Research Co., LtdTiprogrel
P2Y12 receptor antagonist
P2Y12Phase 2Ischemic Stroke–

Conditions

Ischemic Stroke (1)

Modalities

small molecule (1)

Companies

Tianjin Institute of Pharmaceutical Research Co., Ltd (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.